Intravitreal injection of bevacizumab for glioma miultiforme treatment: a case report
Donatella Sarti1, Tiziana Melica2, Stefano Luzi Fedeli1, Giacomo Pellegrini3, Caterina Fiorentini1, Letterio Morabito4, Stefano Guadagni5, Giammaria Fiorentini1*
Affiliation
- 1Department of Oncology-Hematology, Azienda Ospedaliera “Ospedali Riuniti Marche Nord”, 61122 Pesaro, Italy
- 2Department of Clinical Diagnostics, Azienda Ospedaliera “Ospedali Riuniti Marche Nord”, 61122 Pesaro, Italy
- 3Department of Ophthalmology, Azienda Ospedaliera “Ospedali Riuniti Marche Nord”, 61122 Pesaro, Italy
- 4Department of Neurosurgery, Azienda Ospedaliera “Ospedali Riuniti Marche Nord”, 61122 Pesaro, Italy
- 5Department of Applied Clinical Sciences & Biotechnology, University of L’Aquila, 7100 L’Aquila, AQ, Italy, and Alma Mater Europaea – ECM, Slovenska ulica 17, Maribor, Slovenja
Corresponding Author
Dr. Giammaria Fiorentini, Department of Oncology-Hematology, Azienda Ospedaliera Ospedali Riuniti Marche Nord, Presidio Ospedaliero San Salvatore, via C. Lombroso 1, 62122 Pesaro, Italy, Tel: +39 0721364005; Fax +39 0721364094; E-mail: g.fiorentini@ospedalimarchenord.it
Citation
Sarti.D., et al. Intravitreal injection of bevacizumab for Glioblastoma Multiforme treatment: a case report. (2018) J Clin Trials Pathol Case Stud 3(1): 5- 7.
Copy rights
© 2018 Fiorentini, G. This is an Open access article distributed under the terms of Creative Commons Attribution 4.0 International License.
Keywords
Abstract
Tumor angiogenesis depends on Vascular Endothelial Growth Factor (VEGF) secretion to promote neovascularization from existing vessels. In order to block this tumor-induced neo-angiogenesis, anti-VEGF antibody (bevacizumab) has been developed to bind and neutralize all biologically active iso-forms of VEGF). Bevacizumab (BV) is approved by Food and Drug Administration (FDA) for the treatment of recurrent Glioblastoma Multiforme (GBM), resulting in good tumor stability, in association with temozolomide (TMZ).
emsp; GBM is characterized by a poor prognosis and a median overall survival (OS) of 8- 16 months. There is currently no standard treatment options or approaches other than standard chemoradiation for patients with multifocal or single-lesion unresectable GBM.
emsp; In the current study, we present a case of tumor response after intravitreal injection of BV in a patient who progressed to chemoradiation with TMZ. This case report shows that the blockade of neo-angiogenesis by BV was able to induce tumor reduction and response to TMZ.
